Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

Men at high risk of cardiovascular disease had brain volume changes a decade earlier than women, U.K. Biobank data showed.

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden proposes Medicaid, Medicare cover ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Investors are assessing the likelihood Trump will deliver on his threat to impose fresh tariffs on China, Canada and Mexico.

Millions of Americans would be eligible to have costly weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...

U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs, like Novo Nordisk's Wegovy, for more ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

The Endowment made the grants through the latest round of its Religion and Cultural Institutions Initiative, a national initiative launched in 2019 that is supporting efforts to improve the public ...